Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers

Authors

Timothy Voorhees, The Ohio State University Wexner Medical Center, Columbus, OH
Eric McLaughlin, The Ohio State University, Columbus, OH
Pallawi Torka, Memorial Sloan Kettering Cancer Center, New York, NY
Jorge A. Florindez, University of North Carolina, Chapel Hill, NC
Tamara K. Moyo, Atrium Health / Levine Cancer Institute, Charlotte, NC
Heather Reves, University of Texas Southwestern, Dallas, TX
Nuttavut Sumransub, University of Minnesota, Minneapolis, MN
Saarang Deshpande, University of Pennsylvania, Philadelphia, PA
Ashley Rose, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Cassandra Duarte, University of Colorado Cancer Center, Aurora, CO
Muhammad Salman Faisal, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Showkat Hamid, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Suki Subbiah, LSU Health Sciences Center - New OrleansFollow
Sabarish R. Ayyappan, University of Iowa, Iowa City, IA
Lauren Kelly Shea, University of Alabama at Birmingham, Birmingham, AL
Matthew J. Cortese, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Krish Patel, Swedish Cancer Institute, Seattle, WA
Ajay Major, University of Colorado Cancer Center, Aurora, CO
Hayder Saeed, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Jakub Svoboda, University of Pennsylvania, Philadelphia, PA
Sanjal H. Desai, University of Minnesota, Minneapolis, MN
Praveen Ramakrishnan Geethakumari, University of Texas Southwestern, Dallas, TX
Natalie S. Grover, University of North Carolina, Chapel Hill, NC
Narendranath Epperla, The Ohio State University Wexner Medical Center, Columbus, OH

Document Type

Conference Proceeding

Publication Date

11-2-2023

Publication Title

Blood

Abstract

Annual Conference of the Canadian Society of Clinical Chemists (CSCC), June 18-21, 2023, Winnipeg, Canada

First Page

3061

Volume

142

Issue

Supplement 1

Recommended Citation

Voorhees, Timothy; McLaughlin, Eric; Torka, Pallawi; Florindez, Jorge A.; Moyo, Tamara K.; Reves, Heather; Sumransub, Nuttavut; Deshpande, Saarang; Rose, Ashley; Duarte, Cassandra; Faisal, Muhammad Salman; Hamid, Showkat; Subbiah, Suki; Ayyappan, Sabarish R.; Shea, Lauren Kelly; Cortese, Matthew J.; Patel, Krish; Major, Ajay; Saeed, Hayder; Svoboda, Jakub; Desai, Sanjal H.; Ramakrishnan Geethakumari, Praveen; Grover, Natalie S.; and Epperla, Narendranath, "Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers" (2023). School of Medicine Faculty Publications. 4223.
https://digitalscholar.lsuhsc.edu/som_facpubs/4223
10.1182/blood-2023-181056